Perkins Capital Management Inc. Has $2.33 Million Stock Holdings in MDxHealth SA (NASDAQ:MDXH)

Perkins Capital Management Inc. lifted its stake in shares of MDxHealth SA (NASDAQ:MDXH) by 31.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 983,475 shares of the company’s stock after buying an additional 236,100 shares during the quarter. MDxHealth comprises about 2.1% of Perkins Capital Management Inc.’s portfolio, making the stock its 15th largest holding. Perkins Capital Management Inc.’s holdings in MDxHealth were worth $2,331,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Oppenheimer & Co. Inc. lifted its stake in shares of MDxHealth by 100.0% during the 4th quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company’s stock worth $47,000 after buying an additional 10,000 shares during the last quarter. OneDigital Investment Advisors LLC lifted its stake in shares of MDxHealth by 15.3% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock worth $120,000 after buying an additional 7,656 shares during the last quarter. Finally, Maven Securities LTD acquired a new stake in MDxHealth in the 3rd quarter worth about $208,000.

MDxHealth Price Performance

Shares of MDxHealth stock opened at $1.60 on Monday. MDxHealth SA has a twelve month low of $1.35 and a twelve month high of $3.50. The company has a quick ratio of 1.45, a current ratio of 1.54 and a debt-to-equity ratio of 3.14. The company has a 50-day simple moving average of $1.80 and a two-hundred day simple moving average of $2.03. The stock has a market capitalization of $75.66 million, a price-to-earnings ratio of -1.05 and a beta of 1.37.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.07. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. The business had revenue of $24.74 million during the quarter, compared to analysts’ expectations of $22.67 million. Analysts forecast that MDxHealth SA will post -1.15 EPS for the current year.

MDxHealth Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.